Louis Weiner

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. doi request reprint Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies
    Louis M Weiner
    Georgetown University Medical Center, Washington, DC 20057 1465, USA
    Clin Cancer Res 14:502-8. 2008
  2. pmc Antibody-based immunotherapy of cancer
    Louis M Weiner
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007, USA
    Cell 148:1081-4. 2012
  3. pmc Monoclonal antibodies: versatile platforms for cancer immunotherapy
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Nat Rev Immunol 10:317-27. 2010
  4. pmc Vaccine prevention of cancer: can endogenous antigens be targeted?
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road Northwest, Washington, DC 20057, USA
    Cancer Prev Res (Phila) 3:410-5. 2010
  5. pmc Cancer immunotherapy--the endgame begins
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    N Engl J Med 358:2664-5. 2008
  6. pmc Monoclonal antibodies for cancer immunotherapy
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    Lancet 373:1033-40. 2009
  7. doi request reprint Translational Research Working Group developmental pathway for immune response modifiers
    Martin A Cheever
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 14:5692-9. 2008
  8. doi request reprint The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research
    Martin A Cheever
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 15:5323-37. 2009
  9. ncbi request reprint The rollercoaster ride to anti-cancer antibodies
    Louis M Weiner
    Nat Biotechnol 21:510-1. 2003
  10. ncbi request reprint Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
    Kenneth A Foon
    Abgenix, Inc, Fremont, CA, USA
    Int J Radiat Oncol Biol Phys 58:984-90. 2004

Collaborators

Detail Information

Publications39

  1. doi request reprint Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies
    Louis M Weiner
    Georgetown University Medical Center, Washington, DC 20057 1465, USA
    Clin Cancer Res 14:502-8. 2008
    ....
  2. pmc Antibody-based immunotherapy of cancer
    Louis M Weiner
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007, USA
    Cell 148:1081-4. 2012
    ..We discuss these innovative strategies and propose how they will impact the future of antibody-based cancer therapy...
  3. pmc Monoclonal antibodies: versatile platforms for cancer immunotherapy
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Nat Rev Immunol 10:317-27. 2010
    ..These immunomodulatory properties can form the basis for new cancer treatment strategies...
  4. pmc Vaccine prevention of cancer: can endogenous antigens be targeted?
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road Northwest, Washington, DC 20057, USA
    Cancer Prev Res (Phila) 3:410-5. 2010
    ..Obstacles in developing effective cancer vaccines, including antigen selection, immunoediting, and tumor-mediated immunosuppression, are also discussed...
  5. pmc Cancer immunotherapy--the endgame begins
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    N Engl J Med 358:2664-5. 2008
  6. pmc Monoclonal antibodies for cancer immunotherapy
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    Lancet 373:1033-40. 2009
    ..Future treatment modifications or combinations might be able to prolong, amplify, and shape these immune responses to increase the clinical benefits of antibody therapy for human cancer...
  7. doi request reprint Translational Research Working Group developmental pathway for immune response modifiers
    Martin A Cheever
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 14:5692-9. 2008
    ..This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway...
  8. doi request reprint The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research
    Martin A Cheever
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 15:5323-37. 2009
    ....
  9. ncbi request reprint The rollercoaster ride to anti-cancer antibodies
    Louis M Weiner
    Nat Biotechnol 21:510-1. 2003
  10. ncbi request reprint Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
    Kenneth A Foon
    Abgenix, Inc, Fremont, CA, USA
    Int J Radiat Oncol Biol Phys 58:984-90. 2004
    ..Therapy was generally well tolerated without statistically significant adverse events. Monoclonal antibody blockade of EGFR represents a new and exciting direction in cancer therapy...
  11. ncbi request reprint Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Immunother 30:577-90. 2007
    ....
  12. ncbi request reprint Monoclonal antibody therapy of cancer
    Gregory P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
    Nat Biotechnol 23:1147-57. 2005
    ..Progress in the clinical use of radioimmunoconjugates remains hindered by complexity of administration, toxicity concerns and insufficiently selective tumor targeting...
  13. ncbi request reprint Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group
    Hossein Borghaei
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunother 30:455-67. 2007
    ....
  14. ncbi request reprint Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen
    Yong Tang
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    J Immunol 179:2815-23. 2007
    ..Because high affinity may impair in vivo tumor targeting, a careful examination of Ab structure to function relationships is required to develop optimized therapeutic unconjugated Abs...
  15. ncbi request reprint Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer
    Louis M Weiner
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19, 111, USA
    Nat Rev Cancer 7:701-6. 2007
    ..These advances will be complemented by the use of antibodies that induce clinically meaningful host-protective immune responses. But, can we afford this progress?..
  16. ncbi request reprint Monoclonal antibodies in therapy of solid tumors
    David M Heimann
    Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Surg Oncol Clin N Am 16:775-92, viii. 2007
    ..Antibody conjugates have been used to deliver toxic principles, such as radioactive particles, chemotherapeutic agents, and catalytic toxins, with increasing success in clinical trials...
  17. ncbi request reprint Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer
    Kalyani Narra
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1691-9. 2007
    ..The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic colorectal cancer...
  18. doi request reprint Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 31:1-5. 2008
    ..Thus, we performed this phase I study to document the safety and obtain preliminary efficacy data for the combination of capecitabine, oxaliplatin, and bortezomib...
  19. pmc Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy
    Liat Binyamin
    Department of Medical Oncology and Division of Basic Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunol 180:6392-401. 2008
    ..This method provides an alternative approach to potentiate the therapeutic benefit of antitumor Abs that mediate ADCC...
  20. doi request reprint From the Guest Editor: Monoclonal antibodies have emerged as versatile and useful cancer therapeutics
    Louis M Weiner
    Cancer J 14:147-8. 2008
  21. ncbi request reprint Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors
    Robert A Beckman
    Clinical Hematology Oncology, Centocor Research and Development, Inc, Malvern, Pennsylvania 19355, USA
    Cancer 109:170-9. 2007
    ..These manipulations hold the key to promoting tumor exposure and to ultimately creating successful Ab therapies for solid tumors...
  22. ncbi request reprint Targeted therapies in solid tumors: monoclonal antibodies and small molecules
    Louis M Weiner
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Hum Antibodies 15:103-11. 2006
    ....
  23. ncbi request reprint Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed
    Nancy L Lewis
    Division of Medical Science, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 50:257-65. 2002
    ..To determine the maximum tolerated dose (MTD) of raltitrexed when given with irinotecan and to evaluate the pharmacokinetics of these two agents when given in combination...
  24. ncbi request reprint Monoclonal antibody therapy for cancer
    Margaret von Mehren
    Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania 19111, USA
    Annu Rev Med 54:343-69. 2003
    ..Other structural manipulations that improve the selective targeting properties and rapid systemic clearance of immunoconjugates should lead to the design of effective new treatments, particularly for solid tumors...
  25. ncbi request reprint Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma
    Steven J Cohen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:1301-6. 2003
    ....
  26. ncbi request reprint Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647
    Jonathan D Cheng
    Fox Chase Cancer Center, Department of Medical Oncology, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 9:1590-5. 2003
  27. ncbi request reprint Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report
    Melvyn Goldberg
    Fox Chase Cancer Center, Division of Thoracic Surgical Oncology, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    J Thorac Cardiovasc Surg 126:1168-73. 2003
    ..To assess the benefits of aggressive chemoradiation therapy followed by surgery in resectable esophageal carcinoma...
  28. ncbi request reprint Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Cancer Chemother Pharmacol 53:513-8. 2004
    ....
  29. ncbi request reprint Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format
    Lillian S Shahied
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Biol Chem 279:53907-14. 2004
    ..Both minibody constructs are stable in mouse and human serum for up to 72 h at 37 degrees C. These minibodies have the potential to target solid tumors and promote tumor lysis by natural killer cells and mononuclear phagocytes...
  30. ncbi request reprint Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth
    Jonathan D Cheng
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Mol Cancer Ther 4:351-60. 2005
    ....
  31. ncbi request reprint Tunable antibodies
    Louis M Weiner
    Nat Biotechnol 23:556-7. 2005
  32. ncbi request reprint Global gene expression profiling of circulating tumor cells
    Denis A Smirnov
    Immunicon Corporation, Huntingdon Valley, Pennsylvania 19006, USA
    Cancer Res 65:4993-7. 2005
    ..Genes such as AGR2, S100A14, S100A16, FABP1, and others were found useful for detection of CTCs in peripheral blood of advanced cancer patients...
  33. ncbi request reprint Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer
    Lorraine C Snyder
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2412, USA
    Clin Colorectal Cancer 5:S71-80. 2005
    ..The presence of skin rash and EGFR gene amplification have been advanced as possible predictors of clinical effectiveness of targeted anti-EGFR therapies...
  34. ncbi request reprint Fully human therapeutic monoclonal antibodies
    Louis M Weiner
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Immunother 29:1-9. 2006
    ..In addition to providing replacements for existing mAb drugs, new technologies have greatly facilitated the optimization and modification of mAbs, opening numerous therapeutic avenues...
  35. ncbi request reprint Isolation of scFvs to in vitro produced extracellular domains of EGFR family members
    Eva Horak
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Biother Radiopharm 20:603-13. 2005
    ..These scFvs provide a valuable and potentially clinically relevant panel of agents to target the members of the EGFR family...
  36. ncbi request reprint Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report
    Leonard R Henry
    Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
    Ann Surg Oncol 13:214-20. 2006
    ..On the basis of encouraging data from a phase I trial, we conducted a phase II study of preoperative chemotherapy, followed by concurrent chemoradiotherapy and surgery...
  37. ncbi request reprint Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers
    Gregory P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 12:1599-605. 2006
    ..25 %ID/g). These findings substantiate that the improved tumor retention of (sFv')2 homodimers over sFv monomers results from the availability of dual binding sites rather than from the slower systemic clearance of homodimers...
  38. ncbi request reprint A review of antibody therapeutics and antibody-related technologies for oncology
    Bernard J Scallon
    Centocor, Malvern, PA 19355, USA
    J Immunother 29:351-64. 2006
  39. ncbi request reprint Beyond neutrophil recovery: manipulation of the tumor microenvironment by GM-CSF to control cancer
    Louis M Weiner
    Department of Medical Oncology Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 16:7-9. 2002

Research Grants35

  1. Determinants of Tumor Sensitivity to EGFR-Targeted Antibodies
    Louis M Weiner; Fiscal Year: 2010
    ..Specific genes that regulate each of these mechanisms will be identified and exploited to improve antibody therapy. ..
  2. TUMOR TARGETING BY SINGLE CHAIN FV MOLECULES
    Louis Weiner; Fiscal Year: 2002
    ..5 IgG1. These studies will identify candidate molecules for clinical development, and will provide a foundation for the clinically effective radioimmunotherapy of solid tumors. ..
  3. Adaptive Immunity from High Affinity Anti-HER2/neu Monoclonal Antibodies
    Louis Weiner; Fiscal Year: 2006
    ..A candidate antibody for clinical development will emerge, as will generally useful information regarding the structural features of antibodies that contribute to ADCC and in vivo efficacy. ..
  4. Antibody-Targeted NK Cell Activation for Cancer Therapy
    Louis Weiner; Fiscal Year: 2006
    ..The successful execution of these studies will identify candidate strategies for the clinical exploitation of tumor-selective NK cell activation. ..
  5. Antibody-Targeted NK Cell Activation for Cancer Therapy
    Louis Weiner; Fiscal Year: 2007
    ..The successful execution of these studies will identify candidate strategies for the clinical exploitation of tumor-selective NK cell activation. ..
  6. Adaptive Immunity from High Affinity Anti-HER2/neu Monoclonal Antibodies
    Louis Weiner; Fiscal Year: 2009
    ..A candidate antibody for clinical development will emerge, as will generally useful information regarding the structural features of antibodies that contribute to ADCC and in vivo efficacy. ..
  7. ANTIBODY-TARGETED IMMUNOTHERAPY OF CANCER
    Louis Weiner; Fiscal Year: 2002
    ..The successful achievement of these aims will identify new therapeutic reagents and strategies. ..
  8. BISPECIFIC ANTI-TUMOR FC GAMMA R III MONOCLONAL ANTIBODY
    Louis Weiner; Fiscal Year: 1993
    ..Such information will provide future directions for the targeted cellular therapy of cancer...
  9. BISPECIFIC ANTI-TUMOR/FCYR III MONOCLONAL ANTIBODIES
    Louis Weiner; Fiscal Year: 1991
    ....
  10. Adaptive Immunity from High Affinity Anti-HER2/neu Monoclonal Antibodies
    Louis M Weiner; Fiscal Year: 2010
    ..A candidate antibody for clinical development will emerge, as will generally useful information regarding the structural features of antibodies that contribute to ADCC and in vivo efficacy. ..